Data and sample resources

The Zero Childhood Cancer Program (ZERO) is building a rich repository of cancer research resources. Through the ZERO national clinical trial, a bank of tumour samples is being collected, and valuable molecular and genetic information about children’s cancers is being gathered.  

Access to research resources

ZERO’s molecular profiling platform includes whole genome sequencing, RNA sequencing and methylation array data, and aggregate base clinical information from children with cancer of various tissue origins.

Cancer researchers with appropriate regulatory approval have the opportunity to request ZERO samples and data via an application process. Resources that may be requested include: 

  • primary and patient-derived xenograft cells and tissues 
  • WGS, RNAseq and methylation array data. 

Applications received are reviewed by the ZERO Data Access Committee (ZERO DAC), with an expected response time of 4-6 weeks. Patient consent to share collected samples and data is sought at the time of enrolment on the ZERO national clinical trials (PRISM and ZERO2), and all collected material is deidentified to maintain participant privacy and confidentiality.  

Please note that in certain circumstances, the material may need to be recalled for clinical use (such as to enable clinicians to enrol patients onto other trials). 

Cohort Size & trial status
Eligibility Criteria
TARGET Pilot Study
Sydney Children’s Hospital
n=58, closed
High risk and rare paediatric cancer patients with <30% chance of 5-year survival
n>931, closed
High risk and rare paediatric cancer patients with <30% chance of 5-year survival
ZERO2 Study

n>430, currently enrolling

(as of February 2024)

All paediatric cancer patients regardless of risk, type or chance of survival.

Data & Sample Access Policy

ZERO is committed to making ZERO data and samples widely available to researchers within the constraints of human ethics, patient consent and confidentiality and other legal principles governing data storage and release.

Guided by the best practice guidelines and the principles outlined by the National Health Medical Research Council (NHMRC) and the Global Alliance for Genomic and Health (GA4GH), the ZERO Data Access Committee (ZERO DAC) oversees and authorises the access to ZERO's genomic and associated data, and/or biomaterials collected and stored under the custodianship of the ZERO Program at Children’s Cancer Institute Australia. The ZERO DAC provides oversight on access requests to these resources for further research subsequent to their primary purpose approved in the ZERO Program Protocol.

All ZERO Data or Samples access requests for further research beyond the ZERO Program Protocol must be submitted to the ZERO DAC, who will verify, review and assess the feasibility of the proposal and authorise the researchers' access to the data/sample set(s) for further research use.  Approved access to resources will be subject to entry into binding terms and conditions attached to the ZERO Data and Sample access requests which reflect the scope of the applicable patient consents and ethics approvals.  This includes a legal obligation on recipient researchers and their institutions to maintain data security and confidentiality, not to seek to reidentify patients and to use the resources solely for the approved research.  

All applications received after March 15th 2024 will be reviewed by the DAC committee.

Please note that the requirement for ZERO DAC approval for access to resources for further research applies to all researchers whether already participants in the ZERO Program as researchers or clinicians or wholly independent of the ZERO partner organisations.

Researchers requiring access to these resources are invited to submit a ZERO Data or Sample Access Application form that can be found on our web pages here. (See links under “Navigate to:”)

Please visit our updated ZERO Data & Sample Access webpages for more information or reach out to to enquire.

Applicant will typically be notified of the outcomes within 4 weeks of submission. In the event where additional information is requested by the DAC, more time may be required ahead of an application being approved.

To maximize the utility of the rich data within the ZERO cohorts without compromising participant privacy and confidentiality, we have deployed a controlled access data management system. This system enables sharing of de-identified, minimal clinical information, together with individual omics data either in a processed (VCF or TXT) or unprocessed (FASTQ, FASTERQ or BAM) data format, conditional to the justification provided by requesting applicants.

Completion of the ZERO Data Access Application (DAA) or the Sample Access Application (SAA) form and execution of the Data/Material Transfer Agreement is required before access to Data or Sample can be granted. The named investigator of each application will be notified in writing the outcome of their application.

Any changes to a study for which materials or data have been supplied, an Amendment Request must be submitted to reflect any substantial variations, including changes to listed or authorised personnel and the scope of data use. Alternatively, the Investigator(s) and Receiving Institution(s) may be required to sign the Schedule of Special Conditions to confirm acceptance of variations from the Application Form as submitted.

You are strongly recommended to send a preliminary enquiry to before submitting a completed Form so that we can assist you in determining likely sample and data availability.

At the conclusion of a five (5) year follow up period from patient enrolment on ZERO, excess tissue and nucleic acids samples from participants that have consented to future research will be made available to the Children's Cancer Institute Tissue Bank, where access should be sought.

All submitted application form(s) and all supporting documentation must be provided in English. All submissions and enquiries should be addressed to the ZERO DAC via


ZERO Data Access Committee (ZERO DAC)

Access to and use of ZERO Data or Samples is possible through an application to the ZERO Data Access Committee (ZERO DAC). Applications are assessed on the merit of the application based on the following-:

  1. A question has been defined;
  2. The data being sought is relevant to the defined question;
  3. Relevant ethics is in place to conduct the study;
  4. Appropriate research governance is followed by the applicant.

The ZERO DAC may, in its absolute discretion, approve, conditionally approve, reconsider, or reject any applications. Any record of non-compliance to the Terms and Conditions stipulated within their previously executed Data/Sample access applications may impact the Applicant’s eligibility to re-apply for data access in the future.

To view the assessment criteria used to review all ZERO data/sample access applications, please click here to download the DAC review criteria template.

To view the full responsibilities and functions of the ZERO DAC, please click here to download the committee charter.

2024 Submission rounds & DAC meeting dates

Any requests to access ZERO data or samples for research or clinical use must be submitted to the ZERO DAC for review. Please see below for the application closing and DAC meeting dates. Applications are reviewed after each round closing date.












Round open

15th Mar


6th May

3rd Jun

8th Jul

5th Aug

2nd Sept

7th Oct

3rd Dec 

3rd Dec 2024

Round close

8th April

6th May

 3rd Jun

 8th Jul


 2nd Sept

7th Oct

4th Nov


6th Jan 2025

DAC Meeting

 30th April 

28th May

25th Jun

 30th July

 27th Aug

 24th Sept

 29th Oct

 26th Nov


28th Jan 2025

The DAC monthly review cycles do not apply to requests for ZERO Data/Samples that are justifiable for clinical purpose related to the ZERO2 trial or other clinical studies/trials. Ad-hoc request for ZERO data/samples for clinical purposes will be considered and expedited out-of-cycle, as to fulfil the clinical obligations of the ZERO Program. If the request is for research purposes, however, it will be treated as any other research applications regardless of the applicant’s role.

Please contact directly to enquire.

Get in touch

Do you have a question about our work? For any enquiries please don’t hesitate to contact us.